NICE Technology Appraisals (medicines): Formulary Adherence 2019/2020

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA565- Benralizumab for treatingsevere eosinophilic asthma	*6th March 2019*	Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults. ***NHSE Commissioned***	*Y*		*04/06/2019*	*15/05/2019*	*70 days*
TA566 – Cochlear implants for children and adults with severe to profound deafness	*7th March 2019*	Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.	*Y*		*05/06/2019*	*15/05/2019*	*69 days*
TA567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies	*13th March 2019*	Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. ***NHSE Cancer Drug Fund***	*Y*		*11//06/2019*	*15/05/2019*	*63 days*
TA568 – Abatacept for treating psoriatic arthritis after DMARDs	*N/A-appraisal terminated*	NICE is unable to make a recommendation about the use in the NHS of abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because no evidence submission was received from Bristol–Myers Squibb.		*N/A*	*N/A*	*N/A*	
TA569 – Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer	*20th March 2019*	Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults eosinophilic asthma in adults. ***NHSE Commissioned***	*Y*		*18/06/2019*	*15/05/2019*	*56 days*
TA570 - Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy	*20th March 2019 - appraisal terminated*	NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy because no evidence submission was received from Merck Sharp & Dohme.	*N/A*		*N/A*	*N/A*	*N/A*
TA571 – Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib	*20th March 2019*	Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib. ***NHSE Commissioned***	*Y*		*18/06/2019*	*15/05/2019*	*56 days*
TA572 – Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes	*27th March 2019*	Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults. ***CCG Commissioned***	*Y*		*25/06/2019*	*15/05/2019*	*49 days*
TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	*10th April 2019*	Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults. ***NHSE Cancer Drug Fund***	*Y*		*09/07/2019*	*15/05/2019*	*35 days*
TA574 – Certolizumab pegol for treating moderate to severe plaque psoriasis	*17th April 2019*	Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults. ***CCG Commissioned - Blueteq Form***	*Y*		*16/07/2019*	*15/05/2019*	*28 days*
TA575 – Tildrakizumab for treating moderate to severe plaque psoriasis	*17th April 2019*	Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults. ***CCG Commissioned - Blueteq Form***	*Y*		*16/07/2019*	*15/05/2019*	*28 days*
TA576 – Bosutinib for untreated chronic myeloid leukaemia	*17th April 2019 - appraisal terminated*	NICE is unable to make a recommendation about the use in the NHS of bosutinib (Bosulif) for untreated chronic myeloid leukaemia in adults because no evidence submission was received from Pfizer	*N/A*		*N/A*	*N/A*	*N/A*

NICE Technology Appraisals (medicines): Formulary Adherence 2019/2020

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA577 – Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma	*24th April 2019*	Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults. ***NHSE Commissioned***	*Y*		*23/07/2019*	*15/05/2019*	*21days*
TA578- Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation	*1st May 2019*	Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.	*Y*		*30/07/2019*	*19/06/2019*	*49 Days*
TA579 – Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	*8th May 2019*	Evidence-based recommendations on abemaciclib (Verzenios) for hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative locally advanced or metastatic breast cancer in adults who have had endocrine therapy.	*Y*		*6/08/2019*	*19/06/2019*	*42 Days*
TA580 – Enzalutamide for hormone-relapsed non-metastatic prostate cancer	*15th May 2019*	Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.	*N*		*13/08/2019*	*19/06/2019*	*35 Days*
TA581 – Nivolumab with ipilimumab for untreated advanced renal cell carcinoma	*15th May 2019*	Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma that is intermediate - or poor-risk in adults.	*Y*		*13/08/2019*	*19/06/2019*	*35 Days*
TA582 – Cabozantinib for previously treated advanced hepatocellular carcinoma	*24th May 2019 - appraisal terminated*	NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults because Ipsen Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.	*N/A*		*N/A*	*N/A*	*N/A*
TA583 – Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes	*5th June 2019*	Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.	*Y*		*23/07/2019*	*21/08/2019*	*77 days*
TA584 – Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer	*5th June 2019*	Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults. ***NHSE Commissioned***	*Y*		*23/07/2019*	*21/08/2019*	*77 days*
TA585 – Ocrelizumab for treating primary progressive multiple sclerosis	*12th June 2019*	Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults. ***NHSE Commissioned***	*Y*		*30/07/2019*	*21/08/2019*	*70 days*
TA586 – Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib	*26th June 2019*	Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults. **NHS England Commissioned**	*Y*		*13/08/2019*	*21/08/2019*	*56 days*
TA587 – Lenalidomide plus dexamethasone for previously untreated multiple myeloma	*26th June 2019*	Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults. **NHS England Commissioned**	*Y*		*13.08/2019*	*21/08/2019*	*56 days*
TA322- Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality	*26th June 2019* ***(updated)***	Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.	*Y*		*13/08/2019*	*21/08/2019*	*56 days*
TA171 – Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies	*26th June 2019* ***(updated)***	Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.	*Y*		*13/08/2019*	*21/08/2019*	*56 days*

NICE Technology Appraisals (medicines): Formulary Adherence 2019/2020

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA588 – Nusinersen for treating spinal muscular atrophy	*24th July 2019*	Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults. **NHS England Commissioned**	*Y*		*10/09/2019*	*21/08/2019*	*28 days*
TA589 – Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity	*24th July 2019*	Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults. **NHS England Commissioned**	*Y*		*10/09/2019*	*21/08/2019*	*28 days*
TA596 – Risankizumab for treating moderate to severe plaque psoriasis	*21st August 2019* ***Fast Track***	Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults. **CCG Commissioned**	*Y*		*8/10/2019*	*21/08/2019*	*0 days*
TA592 – Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma	*7th August 2019*	Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults. **Cancer Drugs Fund**	*Y*		*24/09/2019*	*18/09/2019*	*42 days*
TA593 – Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	*14th August 2019*	Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy. **Cancer Drugs Fund**	*Y*		*1/10/2019*	*18/09/2019*	*35 days*
TA594 – Brentuximab vedotin for untreated advanced Hodgkin lymphoma	*14th August 2019 Appraisal terminated*	NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults because Takeda did not provide an evidence submission. We will review this decision if the company decides to make a submission.	*N/A*		*N/A*	*N/A*	*N/A*
TA595 – Dacomitinin for untreated EGFR mutation-positive non-small-cell lung cancer	*14th August 2019*	Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults. **NHS England Commissioned**	*Y*		*1/10/2019*	*18/09/2019*	*35 days*
TA597 – Dapagliflozin with insulin for treating type1 diabetes	*28th August 2019*	Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a body mass index (BMI) of at least 27 kg/m^2. **CCG Commissioned**	*Y*		*15/10/2019*	*18/09/2019*	*21 days*
TA598 – Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy.	*28th August 2019*	Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. **Cancer Drugs Fund**	*Y*		*15/10/2019*	*18/09/2019*	*21 days*
TA599 – Sodium zirconium cyclosilicate for treating hyperkalaemia	*4th September 2019*	Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults. **CCG Commissioned**	*Y*		*22/10/2019*	*16/10/2019*	*42 days*

NICE Technology Appraisals (medicines): Formulary Adherence 2019/2020

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA600 – Pembrolizumab with carboplatin and paclitaxel for untreated metastatic non-small-cell lung cancer	*11th September 2019*	Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer. **Cancer Drugs Fund**	*Y*		*29/10/2019*	*16/10/2019*	*35 days*
TA601 – Bezlotoxumab for preventing recurrent Clostridium difficile infection	*25th September 2019*	NICE is unable to make a recommendation on bezlotoxumab (Zinplava) for preventing recurrent *Clostridium difficile* infection in adults because Merck Sharp & Dohme did not provide an evidence submission.	*N*		*12/11/2019*	*16/10/2019*	*21 days*
TA602 – Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma	*25th September 2019 Appraisal terminated*	NICE is unable to make a recommendation on pomalidomide (Imnovid) with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma in adults because Celgene did not provide an evidence submission.	*N/A*		*N/A*	*N/A*	*N/A*
TA603 – Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma	*25th September 2019 Appraisal terminated*	NICE is unable to make a recommendation on lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma in adults because Celgene did not provide an evidence submission.	*N/A*		*N/A*	*N/A*	*N/A*
TA565 – Benralizumab for treating severe eosinophilic asthma	*3rd September 2019* ***(updated)***	Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults. *[In September 2019 NICE removed a statement that benralizumab is not recommended if neither mepolizumab nor reslizumab is recommended. The statement was not needed because if asthma does not meet the criteria for using benzalizumab, then it also does not meet the criteria for using mepolizumab or reslizumab.]* **NHS England Commissioned**	*Y*		*N/A*	*N/A*	*N/A*
TA604 – Idelalisib for treating refractory follicular lymphoma	*2nd October 2019*	Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.	*N*		*19/11/2019*	*20/11/2019*	*49 days*
TA605 – Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea.	*9th October 2019*	Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults. **CCG Commissioned (Blueteq Form req)**	*Y*		*26/11/2019*	*20/11/2019*	*42 days*
TA606 – Lanadelumab for preventing recurrent attacks of hereditary angioedema	*16th October 2019*	Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over. **NHS England Commissioned**	*Y*		*3/12/2019*	*20/11/2019*	*35 days*

NICE Technology Appraisals (medicines): Formulary Adherence 2019/2020

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA607 – Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	*17th October 2019*	Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease. **CCG Commissioned**	*Y*		***4/12/2019***	*20/11/2019*	*34 days*
TA608 – Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia	*30th October 2019 Appraisal terminated.*	NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for treating Waldenstrom's macroglobulinaemia in adults because Janssen did not provide an evidence submission.	*N/A*		***N/A***	*N/A*	*N/A*
TA609 – Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib	*30th October 2019 Appraisal terminated.*	NICE is unable to make a recommendation on ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma in adults who have had sorafenib, because Lilly did not provide an evidence submission. They will review this decision if the company decides to make a submission.	*N/A*		***N/A***	*N/A*	***N/A***
TA590 – Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis	*31st July 2019*	Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults. **CCG Commissioned (Blueteq Form req)**	***Y***		***17/09/2019***	***18/12/2019***	***140 days***
TA591 – Letermovir for preventing cytomegalovirus disease after a stem cell transplant	*31st July 2019*	Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant. **NHS England Commissioned**	***Y***		***17/09/2019***	***18/12/2019***	***140 days***
TA464 – Bisphosphonates for treating osteoporosis	*8th July 2019 - updated*	Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.	***Y***		***N/A***	***N/A***	***N/A***
TA610 – Pentosan polysulfate sodium for treating bladder pain syndrome	*13th November 2019*	Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults. **NHS England Commissioned**	***Y***		***31/12/2019***	***18/12/2019***	***35 days***
TA611 – Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	*13th November 2019*	Evidence-based recommendations on rucaparib (Rubraca) for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults. **Cancer Drugs Fund**	***Y***		***31/12/2019***	***18/12/2019***	***35 days***
TA612 – Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	*20th November 2019*	Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults. **NHS England Commissioned**	***Y***		***7/01/2020***	***18/12/2019***	***28 days***
TA613 – Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy	*20th November 2019*	Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to previous therapy, in adults whose eyes have natural lenses (phakic eyes).	***N***		***7/01/2020***	***18/12/2019***	***28 days***
TA614 – Cannabidiol with clobazam for treating seizures associated with Dravet syndrome	*18th December 2019*	Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older. **NHS England Commissioned**	***Y***		***6/02/2020***	***15/01/2020***	***28 days***
TA615 – Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome	*18th December 2019*	Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older. **NHS England Commissioned**	***Y***		***6/02/2020***	***15/01/2020***	***28 days***

NICE Technology Appraisals (medicines): Formulary Adherence 2019/2020

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	***N/A***	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA616 – Cladribine for treating relapsing-remitting multiple sclerosis	*19th December 2019*	Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults. **NHS England Commissioned**	***Y***		***7/01/2020***	***15/01/2020***	*27 days*
TA617 – Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	*8th January 2020*	Evidence-based recommendations on lusutrombopag (Mulpleo) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure. **NHS England Commissioned**	***Y***		*25/02/2020*	*19/02/2020*	*42 days*
TA618 – Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer	*15th January 2020*	NICE is unable to make a recommendation on atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer, because Roche did not provide an evidence submission. They will review this decision if the company decides to make a submission.	***N***		*03/03/2020*	*19/02/2020*	*35 days*
TA619 – Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	*15th January 2020*	Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adults who have had endocrine therapy. **Cancer Drugs Fund**	***Y***		*03/03/2020*	*19/02/2020*	*35 days*
TA620 – Olaparib for maintenance treatment of relapsed platinu-sensitive ovarian, fallopian tube or peritoneal cancer	*15th January 2020*	Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation. **Cancer Drugs Fund**	***Y***		*03/03/2020*	*19/02/2020*	*35 days*
TA621 – Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer	*22nd January 2020*	Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.	***N/A***		*10/03/2020*	*19/02/2020*	*28 days*